Further, patients with CTEPH demonstrate increased platelet activation and have higher rates of lupus anticoagulant, antiphospholipid antibodies, and factor V Leiden compared to patients with non-CTEPH pulmonary hypertension [23,24]. The gene discussed is F5; the disease is chronic thromboembolic pulmonary hypertension.